FDA
-
-
-
-
-
-
-
BeiGene (BGNE) Announces FDA Accelerated Approval of BRUKINSA
-
-
-
-
-
-
-
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
-
-
-
-
-
-
-
BeiGene (BGNE) Announces Positive Phase 3 Tislelizumab Trial Results
-
-
-
-
-
-
-
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
-
-
-
-
-
-
-
BeiGene's (BGNE) BRUKINSA Demonstrated Superior PFS Over IMBRUVICA in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
-
-
-
-
-
-
-
BeiGene (BGNE) Announces Positive Topline Results from Final PFS Analysis of BRUKINSA Compared to IMBRUVICA in Phase 3 CLL Trial
-
251,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All